Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
Study Details
Study Description
Brief Summary
A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 first in human clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous administration of C1K in healthy Korean subjects.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: C1K 150mg Subcutaneous Administration C1K 150mg single or multi dose |
Drug: C1K 150mg
Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
|
Experimental: C1K 300mg or placebo Subcutaneous Administration C1K 300mg or placebo single or multi dose |
Drug: C1K 300mg
Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
Drug: Placebo with the same volume of C1K 300mg
Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15
|
Experimental: C1K 600mg or placebo Subcutaneous Administration C1K 600mg or placebo single or multi dose |
Drug: C1K 600mg
Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
Drug: Placebo with the same volume of C1K 600mg
Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15
|
Experimental: C1K 900mg or placebo Subcutaneous Administration C1K 900mg or placebo single or multi dose |
Drug: C1K 900mg
Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
Drug: Placebo with the same volume of C1K 900mg
Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15
|
Experimental: C1K 1200mg or placebo Subcutaneous Administration C1K 1200mg or placebo single or multi dose |
Drug: C1K 1200mg
Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
Drug: Placebo with the same volume of C1K 1200mg
Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
|
Outcome Measures
Primary Outcome Measures
- Safety and Tolerability Assessment [Day -1 to Day 23]
Percentage of occurrences observed Adverse Event in each group.
- Safety and Tolerability Assessment by Value Changes in Vital Signs [Day -1 to Day 23]
Vital Signs including blood pressure and heart rate changes from baseline.
- Safety and Tolerability Assessment by Value Changes in Physical Examination [Day -1 to Day 23]
physical examination changes from baseline.
- Safety and Tolerability Assessment by Value Changes in Laboratory Test [Day -1 to Day 23]
laboratory test changes from baseline assessed through hematology, blood biochemistry, urinalysis and blood coagulation.
- Safety and Tolerability Assessment by Value Changes in 12-Lead Electrocardiogram [Day -1 to Day 23]
12-Lead Electrocardiogram(ECG) changes from baseline.
- Safety and Tolerability Assessment by Response Change of Injection site. [Day 1 to Day 23]
Percentage of occurrences observed response change of injection site.
- Pharmacokinetic Assessment by Maximum concentration of C1K in plasma [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Maximum concentration of C1K in plasma (Cmax)
- Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of C1K from Time Zero to the Last Measurable Point [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Area under the plasma C1K concentration-time curve from 0 to last(AUClast)
- Pharmacokinetic Assessment by Area under the plasma C1K concentration-time curve from 0 to infinity [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Area under the plasma C1K concentration-time curve from 0 to last(AUCinf)
- Pharmacokinetic Assessment by The time of peak concentration of C1K [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
The time of peak concentration(Tmax)
- Pharmacokinetic Assessment by Elimination half-life of C1K [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Elimination half-life(t1/2)
- Pharmacokinetic Assessment by Apparent Clearance of C1K [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Apparent Clearance(CL/F)
- Pharmacokinetic Assessment by Apparent Volume of Distribution After extravascular administration of C1K [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Apparent Volume of Distribution After extravascular administration(Vz/F)
- Pharmacokinetic Assessment by Accumulation Ratio of C1K [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Accumulation Ratio(Rac)
- Pharmacokinetic Assessment by Minimum concentration of C1K in plasma [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Minimum concentration of C1K in plasma(Cmin,ss)
- Pharmacokinetic Assessment by Average concentration of C1K in plasma [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Average concentration of C1K in plasma(Cav)
- Pharmacokinetic Assessment by Peak to trough fluctuation ratio [Day 1/ Day 15 pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hour at Day 1 and Day 15]
Peak to trough fluctuation ratio(PTF)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy subjects aged 19 - 45 years at the time of screening visit procedure.
-
The subject weighs in the range of 50.0 - 90.0 kg and has a body mass index (BMI) in the range 18-27 kg/m2.
-
Sufficient ability to understand the study after being informed about the study and provide written informed consent.
-
Based on physical examination, vital sign, 12-lead ECG and laboratory test etc. and in the opinion of the investigator, the subject is suitable for the study.
Exclusion Criteria:
-
A subject with clinically significant hepatobiliary, renal, neurologic, respiratory, endocrine, blood•oncology, cardiovascular, urinary, or, psychical diseases or a history
-
A subject who has difficulty with sub-cutaneous injection(ex: tattoo, allergy on skin etc.)
-
A subject who has hypersensitivity to the drugs of the drugs containing the same class, or other drugs, or a history of clinically significant hypersensitivity
-
A subject who has ventricular tachycardia, ventricular tachycardia, ventricular flutter or confirmed other ventricular flutter and QTc interval: > 450 ms or the other clinically significant medical findings
-
A subject with the following results in the screening test:
-
Blood AST (GOT), ALT (GPT): > Normal range upper × 1.5
-
Blood CPK > Normal range upper × 1.5
-
eGFR (CKD-EPI equation) < 60 mL/min/1.73 m2
-
Positive serological test (syphilis test, hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test)
-
A subject with the following results in the screening test:
-
systolic blood pressure < 80 mmHg or > 140 mmHg
-
diastolic blood pressure < 50 mmHg or > 90 mmHg
-
A subject with a history of drug abuse or positive urine screening test for drug abuse
-
A subject who administered any prescription drugs or herbal medicine within 2 weeks prior to the expected date of the first dose, or any over-the-counter drug (OTC drug) or vitamin within 1 week prior to the expected date of the first dose (However, can participate in the study if otherwise decided eligible by the investigator).
-
A subject who participated in other clinical trial and administered investigational drug within 6 months prior to the expected date of the first dose
-
A subject who donated whole blood within 2 months or the component blood within 1 month prior to the expected date of the first dose, or received blood transfusion within 1 month prior to the expected date of the first dose
-
Smokers who smoke more than 10 cigarettes/day in the last 3 months as of screening day.
-
A subject with persistent alcohol intake (> 21 units/week, 1 unit = 10 g of pure alcohol), or inability to abstain from drinking from 3 days before the expected date of the first dose until the last discharge
-
A male subject who has plan to have a baby or to donate sperm. A female subject who is pregnant or lactating or has plan to lactate within 3 months after administration of IP
-
A subject who is intending to become pregnant during this study or with inability to use a medically acceptable contraception method(ex. sterilization operation, intrauterine device etc. for Subject or subject's partner
※ medically acceptable contraception method
-
Use of intrauterine device which is proven pregnancy failure rates in spouses (or partners).
-
Use combined blocking contraceptives (for male or female) and antiseptic drugs
-
Subject or partner's operation(vasectomized, bilateral tubal occlusion, hysterectomy)
- Subject who is considered inadequate to participation in the study due to other reason under investigator's discretion
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Seoul National University Hospital | Seoul | Korea, Republic of |
Sponsors and Collaborators
- Ensol Bioscience
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- C1K-101